Loading...

Discussions on Successful Partnerships

RESI AI is proud to highlight active investors and early-stage founders advancing drugs, devices, diagnostics, and digital health through the power of AI. Innovative, smart technology with creative applications take center stage alongside insights around how to navigate the early-stage investment ecosystem.

RESI AI hosts panels where active investors in the space are joined by their portfolio companies to discuss funding, partnerships, and the future of AI in life science and healthcare. Do you have a strong, successful partnership that deserves to be highlighted on a panel? Apply to participate and tell us why!

Panel Application

September 16 | 10 AM EDT

Healthcare Communications
Bridging the Gaps between Patient and Provider
Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time. 

Colette Courtion, MBA, CEO, Joylux
A distinguished and award-winning consumer marketer, inventor, and business leader who leverages over 20 years of cross-functional expertise steeped in brand building, marketing, strategic planning, and finance with leading consumer product, retail and medical device companies to open up and grow new ventures. Founder of three venture-backed consumer/ health and beauty-related startups based in Seattle, Washington, known as innovative category leaders with thousands of highly-satisfied customers served. Brand and product architect adept at identifying new growth potential from conception through successful execution while utilizing a highly resourceful approach to solving complex problems along the way. Author of multiple international patents. Extremely knowledgeable about consumer market trends, technologies, and consumer needs in the health and beauty industries. Colette has been named by the Puget Sound Business Journal as one of the Top 15 Women of Influence in Seattle (2009) and Top 40 Under 40 leaders in Seattle (2006), and has actively supported non-profits in leadership roles including Seattle Art Museum Supporters and PONCHO.

Tanja Dowe, CEO, Debiopharm Innovation Fund (Moderator)
Tanja is the CEO of Debiopharm Innovation Fund, the digital health investment arm of Debiopharm located in Lausanne, Switzerland. With 150M under management, the fund invests in smart data and digital health start-ups that improve patient journeys and pharmaceutical R&D. Prior to joining Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder/CEO at BioSolutions INT. Tanja is an experienced board member and chairwoman with a track record of successful M&A exits. She holds an MSc in Applied Microbiology and Biochemistry from Helsinki University of Technology.

Cory Kidd, PhD, CEO, Catalia Health
Dr. Cory Kidd is the founder and CEO of Catalia Health. Dr. Kidd has been working in healthcare technology for nearly two decades. The focus of his work has been applying innovative technologies towards solving large-scale healthcare challenges. His previous company, Intuitive Automata, created interactive coaches for weight loss. Prior to this, Dr. Kidd received his M.S. and Ph.D. at the MIT Media Lab in human-robot interaction. While there, he conducted studies that showed the psychological and clinical advantages of using a physical robot over screen-based interactions.

Lu Zhang, Managing Partner, Fusion Fund
Lu Zhang is the Founding and Managing Partner of Fusion Fund. Lu is a World Economic Forum – Young Global Leader (Class of 2018). She has also garnered other accolades including the Featured Honoree in VC of Forbes 30 Under 30 (2017), Silicon Valley Women of Influence (2018), Town & Country 50 Modern Swans – Entrepreneurship Influencer (2017), and Top 10 All America Chinese Youth (2018). Prior to starting Fusion Fund, she was the Founder and CEO of a medical device company focused on non-invasive technology for the early diagnosis of Type II diabetes (acq 2012). Lu is a frequent speaker at tech events and conferences and also serves as a mentor and advisor to several tech innovation programs in Silicon Valley. Lu is the board member of the Youth Council of Future Forum and Future Science Award. She received her MS in Materials Science and Engineering from Stanford University.

Ron Zink, JD, Member, Alliance of Angels
Ron is a member of the Alliance of Angels and Vice President of Product Development & Strategy at Trace Genomics. He has previously held technology and business development leadership roles at Growers Holdings, John Deere and Microsoft in the U.S. and Europe. He holds a BS in Electrical & Computer Engineering from North Dakota State University as well as a Juris Doctorate Degree in Law from the University of North Dakota School of Law.

September 17 | 10 AM EDT

Accelerated Pharmaceutical Development
Advancing and Optimizing Clinical Processes
AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Kareem Barghouti, Co-Founder & CEO, VastBiome
Kareem Barghouti is the Co-Founder and CEO of VastBiome. He received his BS in Biological Sciences at UC Irvine and an MBA from Duke University with a concentration in Healthcare Sector Management. His background is in Strategy & Operations and Sales & Marketing. Kareem joined the fast-growing startup Wildfire Interactive as a Business Development rep which was acquired by Google for $450M. He spent 5 years at Google leading the data integrity of Google’s advertising business, managing teams of 100+, and was part of the core product team to launch an online education portal to millions of users globally. He was recognized as the top sales rep globally (1000+ reps) for the New Business Sales team. Most recently, Kareem participated as a Biodesign Fellow at the Texas Medical Center Innovation Institute in Houston, Texas, where VastBiome was born.

Marina Cortes, Venture Partner, Hike Ventures
Marina is a multilingual professional equipped with a background in health research and a unique skill-set acquired through her experience in Consulting and Venture Capital. She started her career in healthcare investment at BDC Capital and later joined an advisory team, wherein she notably advised private companies on IPO dual listing (HKEX, NYSE) and due diligence M&A buyer side. Later on, she oversaw the global strategy of Heartbeat AI and developed strategic partnerships in Japan and South Korea. Meanwhile maintaining key investor relations she gained a keen interest in VC fundraising and LP relations and advised several LPs and GPs on VC/PE fundraising in North America and Asia. Marina has a strong passion for VC fund operations, investor relations, and, enjoys helping startups and organizations expanding to international markets. BS from the University of Montreal; MS from Seoul National University.

Anastasiya Giarletta, Principal, R42 Group (Moderator)
Anastasiya is a Principal at the R42 Group, based in Silicon Valley and London, evaluating companies in longevity science and artificial intelligence. She also manages the R42 Institute, which mentors the next generation of founders in longevity and AI. Previously, Anastasiya co-founded Aikora Health, focused on the longevity biotech ecosystem. She holds a Master’s degree in Sustainable Development from St. Andrews University.

Neel Madhukar, PhD, Co-Founder & CEO, OneThree Biotech
Neel S. Madhukar obtained his PhD from Weill Cornell under the direction of Olivier Elemento, where his research focused on designing new machine learning approaches that are better suited for biological problems. While at Cornell, he authored numerous scientific publications in the fields of machine learning, pharmacology, and precision medicine. To date, his work has led to the development of new AI prediction methods, the discovery of a novel class of cancer therapeutics, and the start of new clinical trials. He then went on to complete postdoctoral studies at Cornell Tech’s Runway Postdoc program where he developed OneThree Biotech. Currently he leads OneThree’s overall strategy and research direction. Dr. Madhukar is an awardee of the PhRMA informatics fellowship, was named one of Forbes “30 under 30” leaders in healthcare, and was listed as one of the top 100 AI Leaders in Drug Discovery and Advanced Healthcare.

Brad Svrluga, Co-Founder & General Partner, Primary Venture Partners
Brad is a co-founder and General Partner at Primary. He has been a venture investor since the waning moments of the Internet bubble in 2000, when he joined one of the dozens of micro-firms that popped up at the time, but likely never should have. He was previously a strategy consultant with Monitor Group, leading projects out of the firm’s Cambridge, South Africa and Brazil offices. Brad focuses his investing activities on B2B application businesses. At Primary, he has led the firm’s successfully exited investments in Ticketfly (sold to Pandora), TxVia (sold to Google), Divide (sold to Google), Pump Audio (sold to Getty Images), Threadsmith (sold to Vistaprint) and Allworx (sold to PAETEC). At BCI, amongst the investments he was responsible for were HealthShare (sold to WebMD) and Profile Systems (sold to AT&T). Brad co-founded Primary predecessor fund High Peaks Venture Partners, and in 2015 launched Primary with General Partner Ben Sun. He is an active participant in the NYC venture community, and writes not frequently enough on his blog, Can I Buy a Vowel?. Brad is a graduate of Williams College, where he captained the rugby team and majored in economics.

September 16 | 4 PM EDT

Healthcare Systems and Infrastructure
Creating Synergy for Efficient Patient Care
Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally. 

Jeff Chang, Co-Founder & CPO, Rad AI
In the past decade, Dr. Jeff Chang has read nearly a quarter million X-rays, CTs, ultrasounds and MRIs. After starting medical school at age 16, Jeff became the youngest radiologist on US record. Fellowship-trained in musculoskeletal MRI, he worked as an ER radiologist for 9 years. Troubled by high error rates, worsening radiologist burnout, and rising imaging demand with a growing shortage of radiologists, Jeff decided to take action. He pursued graduate work in machine learning to identify ways in which AI could help. Along the way, he met co-founder Doktor Gurson, a serial entrepreneur with experience in tech. Rad AI was born at this intersection between radiology and AI.

Bradley Erickson, MD, PhD, CMO, FlowSIGMA; Medical Director for AI, Mayo Clinic (Moderator)
Bradley J. Erickson, MD, PhD is the Medical Director for AI at Mayo Clinic, and Chief Medical Officer for FlowSIGMA. He directs a research lab of about 20 post-doctoral fellows with projects in computer-aided diagnosis and the use of computer technologies to extract information from medical images for diagnostic, prognostic and therapeutic purposes. This research includes the development and validation of algorithms to detect progression, regression or risk of disease, and the prediction of molecular markers from medical images. Other teams work with other types of radiology images as well as dermatology images and histopathology images.

Amit Garg, MBA, Managing Partner, Tau Ventures
Amit is currently Managing Partner at Tau Ventures, a $15M seed fund in Palo Alto focused on applied AI in digital health, automation (cars, drones, robots), and enterprise. Key investments he has worked on in the past include UniKey (smart locks), nuTonomy (self-driving cars, sold for $450M), BioBeats (machine learning for human well-being, acquired by Huma / Medapod), Glooko (diabetes management), Cohero Health (respiratory management), Terapede (low-dosage X-ray detection), Figure1 (medical communication), HealthifyMe (fitness and health-tracking), Healthy.io (home-based urinalysis) and RapidDeploy (cloud-based emergency response). He has been in Silicon Valley for 20 years — at Samsung NEXT Ventures, cofounded a startup called HealthIQ (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. His academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. He speaks natively 3 languages, live carbon-neutral, is a 70.3 Ironman finisher, and has built a hospital in rural India serving 100,000 people.

Saar Mahna, MBA, Founder & CEO, Banjo Health
Saar Mahna is Founder & CEO of Banjo Health, an innovative healthcare technology solution provider that enhances existing practices through Artificial Intelligence (AI). Saar founded Banjo with the mission to clear the path for our healthcare partners to focus on optimal patient care by providing innovative, effective, and efficient technological solutions to overcome administrative barriers.

Dalton Wright, MBA, Partner, Kickstart Fund
Dalton is a technological optimist who loves his role in venture capital where he gets to meet and support a wide variety of extraordinarily talented entrepreneurs who endeavor to build consequential companies. His expertise is founder support on the early startup journey, including ideation, opportunity identification, product/market fit, business model, team-building, fundraising, and GTM strategies. Dalton’s roots with Kickstart go back to the beginning in 2008 when he helped launch the fund and, later, Kickstart’s student-run Campus Founders Fund (CFF). Dalton also assisted in founding Mexico’s first early-stage tech fund. Today, his investment focus centers around data networks, analytics, ML/AI, blockchain, and health IT. His superpower is his openness to new ideas, people and possibilities and wishes he could live far into the future to see what we are building.

September 17 | 2 PM EDT

Diagnostic Wearables
Connecting Patients to Their Health
Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health. 

Paul Barbeau, CTO, Noetic Fund

Paul Barbeau has led numerous complex enterprise projects across multiple sectors including government, legal, medical, private and public companies over the past 20+ years. He has held C-Level roles in private and public companies, and has developed and deployed Clinically Proven technology for Hospitals and Patients in Canada. He has robust data security experience and numerous certifications, and was named a Top 40 under 40 in Ottawa.

Alicia Chong Rodriguez, Founder & CEO, BloomerTech
Alicia Chong Rodriguez is the CEO at Bloomer Tech. She graduated from the MIT Electrical Engineering & Computer Science program and MIT IDM, where her research focused on sex-specific, computationally-generated, cardiac biomarkers at the MIT Computational Cardiovascular Research Group. She received the MIT Legatum Fellowship and the MIT Graduate Women of Excellence Award. She has also been recognized as a 2021 TED Fellow, 2018 Medtech Boston 40 under 40 Healthcare Innovator, and in the top 100 Female Founders across the U.S. by Inc Magazine. Prior to MIT she worked in the semiconductor industry at companies such as HP and Teradyne and co-founded MenTe en Acción (Mujeres en Tecnología) where she currently serves on the board as a technical advisor.

Gary Gershony, MD, Founding General Partner, BayMed Venture Partners; Director, Cardiovascular Research, Education and Technology, John Muir Health; Angel Investor (Moderator)
Dr. Gershony grew up in Toronto, Canada and attended the University of Toronto where he graduated from medical school at age 23. He continued his training in internal medicine and general cardiology at the University of Toronto where he also served as Chief Medical Resident. Dr. Gershony continued his training in interventional cardiology, serving a fellowship at Emory University in Atlanta under the auspices of Dr. Andreas Grüntzig, the inventor of coronary and peripheral angioplasty. From 1993-1997, Dr. Gershony was Director of the Cardiac Catheterization Laboratories and Interventional Cardiology at the University of California, Davis, Medical Center. For the past 20 years he has practiced interventional cardiology at John Muir Cardiovascular Institute in the San Francisco Bay Area where he is currently the Director of Cardiovascular Research, Education and Technology, and has established a successful Transcatheter Aortic Valve Replacement (TAVR) program.

Richard Hanbury, MBA, Founder & CEO, Sana Health
Richard developed Sana’s neuromodulation platform to eradicate his own life-threatening pain problem following a spinal cord injury from a jeep crash in Yemen in 1992. It is now his life’s mission to help as many people as possible find relief. He previously founded a software startup, and before that worked for McKinsey. He has spent 28 years developing Sana’s technology from the original benchtop device to the current device undergoing clinical trials. What he most loves about leading Sana Health is hearing story after story from Sana users who say that Sana gave them their life back. Richard obtained an MBA from the Wharton School and a Diploma in Law from College of Law London.

Adam Sharkawy, PhD, Co-Founder & Managing Partner, Material Impact Fund
Adam is Co-Founder and Managing Partner of Material Impact. An accomplished executive healthcare and life sciences leader, Adam brings his track record of building and leading material-based centers of innovation within several large corporates and extensive experience on both sides of acquisition transactions to the Material Impact team. His worldwide leadership spans US, International, and Emerging markets. Adam’s successful career as a seasoned executive leader and entrepreneur in the Healthcare and Life Sciences sector encompasses a diverse background across technologies (devices, bioactives, and biologics), therapy spaces (interventional, cardiovascular, surgery, orthopedics, etc) and different business environments (leading small entrepreneurial VC-funded to large Fortune 500 corporate).

September 17 | 4 PM EDT

Precision Medicine
Fitting the AI Piece of the Puzzle
The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, and tackle manufacturing and commercialization challenges. 

Jessica Gibson, MBA, Co-Founder & CEO, ARIEL Precision Medicine
Jessica is the CEO and co-founder at Ariel. Her background in genomics, healthcare and pharma is now enabling Ariel to create strategic partnerships and collaborations that serve multiple customers in the healthcare community. Jessica loves working at Ariel because she has been able to build innovative solutions to enable the diagnosis and management of chronic diseases and really move the needle on a number of challenging conditions.

Jens Kelm, PhD, Co-Founder & CEO, PreComb Therapeutics
Jens M. Kelm is one of the pioneers and initial developers of 3D tissue culture technology. He was founder, president and CSO of InSphero AG, commercializing physiological 3D models, assays and screening concepts. He is co-founder of the Swiss competence center for 3D cell culture technologies (TEDD) and member of the steering committee of the 3D cell culture conference series 3DCC organized by the DECHEMA. Jens has published more than 50 publications and 11 Patents in the field. He holds a PhD in Biotechnology from the ETH Zürich.

Chris Moehle, PhD, MBA, Managing Director, The Robotics Hub
Chris Moehle is a Pittsburgh, Pennsylvania-based entrepreneur who focuses on driving innovative technology development as the head of The Robotics Hub accelerator and venture fund. Emphasizing an agile, value-added approach, Chris Moehle rapidly identifies and invests in companies that are capable of driving disruptive change that benefits society. Active on the boards of Agility Robotics, Ariel Precision Medicine, and JDV Robotics amongst others, Moehle spends a significant amount of time after investment helping companies reach their full disruptive potential. This can be everything from high-level strategy and product design assistance to making sales calls and operational plans. Chris has spent a huge amount of his professional time advocating for and encouraging the responsible deployment of advanced technologies, dating back to previous positions at Carnegie Mellon’s National Robotics Engineering Center, PWC’s Public Sector Advisory, and the University of Virginia Department of Surgery.

Maria Luisa Pineda, PhD, Co-Founder & CEO, Envisagenics
Maria Luisa Pineda, PhD, is the Co-founder and CEO of Envisagenics. Dr. Pineda has over a decade of experience as a researcher and, before starting Envisagenics, she was a life science venture capital investor. Under her leadership, Envisagenics has received non-dilutive SBIR grants from the National Institutes of Health, generated significant revenue from Biopharma, raised capital from investors like Microsoft’s VC arm (M12), and won several prestigious artificial intelligence competitions, including the JLABS Artificial Intelligence for Drug Discovery QuickFire Challenge. To date, Dr. Pineda has secured research collaborations with Biogen and the Lung Cancer Initiative at Johnson & Johnson. She looks forward to closing more commercial partnerships in the near future to accelerate drug development with the help of SpliceCore®, Envisagenics’ AI platform that develops novel therapeutics for RNA splicing variants.

Stephen Pitt, PhD, Head, Johnson & Johnson Innovation, JLABS US North East (Moderator)
Stephen Pitt, PhD is the Head of Johnson & Johnson Innovation, JLABS US North East which includes the JLABS @ NYC, JPOD @ Boston, JLABS @ LabCentral, JLABS @ M2D2 and JPOD @ Philadelphia. He is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. He catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer and healthtech sectors. Steve joins JLABS from GlaxoSmithKline, where he was Senior Director of Emerging Science Innovation and Head of the Digital Innovation Hub R&D Team. At GSK, Steve led externally focused R&D teams that shifted pipeline strategies from basic symptom relief to holistic disease management to transform self-care. He also created partnerships with academic institutions, start-ups, corporate partners, hospital systems, and other novel outsourcing collaborators with the aim to build breakthrough technology platforms and products. Prior to GSK, he continually increased his responsibility as an R&D leader over 15 years in drug discovery, pharmaceutical development and consumer healthcare at Johnson & Johnson, Pfizer, Bayer, and in biotech. His experiences include drug discovery and advancing compounds to clinical trials, pharmaceutical development and commercialization of novel Rx Drugs, and consumer health product development in upstream innovation groups to shape and launch new external technologies. Steve earned his PhD in Molecular Pharmacology from Cornell Medical School and Memorial Sloan Kettering Cancer Center in New York City. At Cornell, Steve pioneered computational molecular dynamic drug discovery approaches. He also holds several patents and has published in top scientific journals.

Angelika Vlachou, MBA, PhD, Senior Investment Manager, High-Tech Gründerfonds
Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.